Symbiotec Pharmalab IPO GMP Today

GMP for Symbiotec Pharmalab IPO started at Rs 220 on 19 August 2026 and stood at Rs 410 on 23 August 2026. That is roughly a 1.9x move over 5 days of tracked data. The sharpest single-day jump was from Rs 220 on 19 Aug 2026 to Rs 300 on 20 Aug 2026. The upward move through the subscription window usually reflects building demand across investor categories rather than a one-day spike. GMP typically moves more in the final two to three days before the close date, especially after QIB and HNI bids come in.

Based on today's GMP, Symbiotec Pharmalab IPO listing price estimate is Rs 1,398.00 per share (issue price Rs 988.00 + GMP Rs 410.00).

Actual listing price will be known on 1 September 2026 when the stock lists on NSE/BSE.

A GMP of around 41.5% is a strong positive signal from the grey market. Investors are pricing in a meaningful listing premium over the issue price.

GMP has moved up over the tracked period. Steady increases through the subscription window are usually a stronger signal than a single-day spike.

GMP is unofficial. Listing gain can differ on listing day.

GMP and subscription numbers often move together. When institutional and HNI demand is strong, grey market participants usually price in a higher premium. Current overall subscription for Symbiotec Pharmalab IPO is -. Compare this with the GMP trend to see if demand aligns. The GMP move around 20 Aug 2026 may reflect how the market reacted once the subscription window activity picked up after 24 Aug 2026.

See live figures on the Symbiotec Pharmalab IPO Subscription Status page.

Symbiotec Pharmalab IPO full details (financials, peers, review).

Symbiotec Pharmalab Limited (incorporated in 2002) is an established research-driven pharmaceutical and biotechnology company specializing in the development and manufacturing of Active Pharmaceutical Ingredients (APIs), particularly corticosteroids and steroidal-hormone APIs, alongside contract development and manufacturing (CDMO) services and complex injectables. The company operates industrial-scale manufacturing facilities at Rau and Pithampur SEZ in Madhya Pradesh with US FDA, EU-GMP, and WHO-GMP approvals, alongside newly commissioned biomanufacturing facilities in Ujjain and dedicated complex injectables facilities in Mhow. As of March 31, 2026, Symbiotec served over 200 customers across more than 40 countries, holding 43 US FDA Drug Master Files (DMFs) and 23 European Certificates of Suitability (CEPs).